Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06362395
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-02-26
Brief Title:
Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ULTRAS
Brief Summary:
This international multi-centre phase 3 randomized control trial investigates whether giving a very high dose of radiation in a single treatment session ultra-high dose experimental using advanced technology called MR-Linac is more effective than a high dose control for treating liver tumors that have spread from other parts of the body liver metastases This study also aims to identify predictors of treatment response and side effects by analyzing various factors such as imaging markers and genetic profiles
Liver metastases are common in several cancers but surgery is often not feasible for many patients Stereotactic body radiotherapy SBRT which delivers focused radiation to tumors is an alternative treatment option Previous studies have shown promising results with SBRT but the optimal radiation dose for liver metastases is still uncertain
This study will look at patients with specific types of primary cancers known to respond well to SBRT Treatment effectiveness will be assessed by monitoring tumor control overall survival and quality of life
By comparing ultra-high dose SBRT with standard high dose the study aims to determine if the former can provide better tumor control with fewer side effects If successful this approach could offer a significant advancement in the treatment of liver metastases potentially improving outcomes and quality of life for patients
Liver metastases are common in several cancers but surgery is often not feasible for many patients Stereotactic body radiotherapy SBRT which delivers focused radiation to tumors is an alternative treatment option Previous studies have shown promising results with SBRT but the optimal radiation dose for liver metastases is still uncertain
This study will look at patients with specific types of primary cancers known to respond well to SBRT Treatment effectiveness will be assessed by monitoring tumor control overall survival and quality of life
By comparing ultra-high dose SBRT with standard high dose the study aims to determine if the former can provide better tumor control with fewer side effects If successful this approach could offer a significant advancement in the treatment of liver metastases potentially improving outcomes and quality of life for patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None